Nephros (NASDAQ:NEPH – Get Free Report) and InterCure (NASDAQ:INCR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.
Risk and Volatility
Nephros has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Nephros and InterCure, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nephros | 0 | 1 | 1 | 0 | 2.50 |
| InterCure | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Nephros and InterCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nephros | 4.06% | 7.66% | 5.86% |
| InterCure | N/A | N/A | N/A |
Institutional and Insider Ownership
41.1% of Nephros shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Nephros and InterCure”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nephros | $19.12 million | 1.90 | $1.19 million | $0.07 | 47.71 |
| InterCure | $78.47 million | 0.57 | -$10.37 million | $0.03 | 27.07 |
Nephros has higher earnings, but lower revenue than InterCure. InterCure is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.
Summary
Nephros beats InterCure on 13 of the 14 factors compared between the two stocks.
About Nephros
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
About InterCure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.
